Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
4
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
4
×
san diego top stories
san francisco blog main
san francisco top stories
fda
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
akcea therapeutics
allergan
alnylam pharmaceuticals
andrew fire
arena pharmaceuticals
biotech
blueprint medicines
boston
bristol-myers squibb
cardiovascular disease
clinical data
What
drug
4
×
medicine
4
×
approved
fda
cancer
new
afternoon
alnylam
alnylam’s
data
deeper
disease
dna
eisai
fatty
fingerprint
flags
genetic
gets
going
higher
history
horizon
incidence
intercept
known
landmark
liver
lorcaserin
loss
making
market
marketed
marketing
matter
nash
nd
nonalcoholic
ok
oks
Language
unset
Current search:
medicine
×
drug
×
" clinical trials "
×
" san diego blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug